| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenue | 15 | 27 | ||
| Cost of revenue | 0 | 0 | ||
| Research and development | 3,513 | 3,514 | ||
| General and administrative | 2,150 | 2,377 | ||
| Total operating expenses | 5,663 | 5,891 | ||
| Loss from operations | -5,648 | -5,864 | ||
| Interest income | 40 | 62 | ||
| Interest expense | 649 | 679 | ||
| Change in fair value of common stock warrant liabilities | 1,728 | 515 | ||
| Change in fair value of derivative liabilities | -797 | -439 | ||
| Change in fair value of clene nanomedicine contingent earn-out liability | 0 | 0 | ||
| Change in fair value of initial stockholders contingent earn-out liability | 0 | 0 | ||
| Research and development tax credits and unrestricted grants | 5 | 16 | ||
| Total other income (expense), net | -3,129 | -1,555 | ||
| Net loss before income taxes | -8,777 | -7,419 | ||
| Income tax expense | 0 | 0 | ||
| Net loss | -8,777 | -7,419 | ||
| Unrealized loss on available-for-sale securities | 0 | 0 | ||
| Foreign currency translation adjustments | 1 | 63 | ||
| Total other comprehensive income | 1 | 63 | ||
| Comprehensive loss | -8,776 | -7,356 | ||
| Net loss per share basic and diluted (in dollars per share) | -0.85 | -0.78 | ||
| Weighted average common shares used to compute basic and diluted net loss per share (in shares) | 10,284,674 | 9,523,592 | ||
Clene Inc. (CLNNW)
Clene Inc. (CLNNW)